Phio Pharma Q2 EPS $(3.62) Misses $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Phio Pharma (NASDAQ:PHIO) reported a Q2 EPS loss of $(3.62), significantly missing the analyst consensus estimate of $(0.51) by 609.8%. This represents a 72.64% improvement over the $(13.23) loss per share from the same period last year.
August 14, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Phio Pharma reported a Q2 EPS loss of $(3.62), missing the analyst estimate of $(0.51) by a wide margin. Despite the miss, the loss is an improvement from the $(13.23) per share loss in the same period last year.
The significant miss on EPS estimates is likely to negatively impact the stock price in the short term. However, the year-over-year improvement in losses may provide some cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100